ZhilianhaiCompany Profile: Zimmer Biomet Holdings, Inc.
Company and ROSA portfolio
Zimmer Biomet Holdings, Inc. supplies musculoskeletal technologies, including implants and robotic assistance. Its ROSA portfolio includes knee, hip and shoulder applications, while ROSA ONE addresses neurosurgical procedures. These are procedure-specific systems within the company's offering. A hospital should identify the application, software and compatible implants before comparing a ROSA proposal with another robotic platform. ROSA portfolio; Corporate identity.
ROSA Knee with OptimiZe
The current knee page presents ROSA Knee with OptimiZe, with planning, anatomical landmarking, tracking and configurable workflow features for total knee arthroplasty. Its planning tools support implant-positioning choices using the surgeon's balancing preferences. These functions assist clinical judgment; their presence does not establish a universal alignment strategy or predictable outcome for every patient. Current knee system.
Zimmer Biomet announced US FDA clearance for the enhanced knee version on November 14, 2025, describing an initial targeted release and wider US commercial availability expected in early 2026. Buyers should confirm which release is available locally and what changes an existing installation needs to support it. Dated OptimiZe announcement.
Hip and shoulder workflows differ
The ROSA Hip page describes a fluoroscopy-based workflow aligned with the direct anterior approach and identifies compatible hip systems including Avenir Complete and G7. That imaging arrangement should not be generalized to all ROSA applications. Planning and equipment requirements need to be checked for the specific procedure. ROSA Hip workflow.
ROSA Shoulder instead describes CT-based planning through Signature ONE Planner and robotic assistance for glenoid and humeral preparation. The product page lists Comprehensive, Identity and Alliance shoulder systems. Its collaborative mode allows surgeon movement of the arm while the robot maintains elements of control. Compatibility must be established for the actual implant and software configuration. Shoulder planning and components.
2026 shoulder evidence and clinical introduction
The FDA's May 21, 2026 K260582 letter identifies the ROSA Shoulder System and applicant Orthosoft Inc., doing business as Zimmer CAS. Zimmer Biomet announced the expanded system the following day, describing support for both glenoid and humeral preparation in anatomic and reverse techniques. This evidence applies to the named shoulder system, not every product carrying the ROSA brand. FDA K260582; May 2026 announcement.
The company's August 5, 2026 results update reports completion of first cases with the next-generation shoulder system. It is a dated manufacturer statement of clinical introduction, without a site-level installation count or comparative clinical result in that summary. First-case update.
Training and program implementation
Zimmer Biomet provides professional education resources, events and access to its institute network. The shoulder page also supplies a sterilization aid and planning resources. A complete implementation proposal should cover surgeon education, staff competencies, imaging and case-planning responsibilities, sterile processing, application support and service escalation. Public educational material does not replace training for the exact system installed. Professional education; Application resources.
Questions for an orthopedic procurement team
Which ROSA application, hardware and software release are proposed?
Which implants and instruments are compatible and authorized in the destination market?
Does the selected workflow require CT, fluoroscopy, tracking equipment or external planning services?
Who owns planning turnaround, case-data access, cybersecurity and software maintenance?
What training, initial case support, recurring disposables and service coverage are included?
Can a relevant reference site and a measurable installation-acceptance plan be provided?
International procurement and official contact
Zimmer Biomet provides a corporate contact directory, while its product pages offer routes to a representative. The company reports an international business footprint, but this does not establish that every ROSA version is available in every country. A request should name the destination, procedure, facility type, current implant usage and implementation window, then ask for local authorization and service documentation. Official contact directory; International corporate context.
Evidence limits and buyer resources
The cited manufacturer pages describe products and reported activity; the FDA document concerns a specific US device clearance. Neither supplies a guarantee of clinical benefit, universal compatibility or global availability. In particular, laboratory accuracy descriptions should not be treated as proof of better outcomes for every patient. Shoulder evidence qualifications.
Continue with Medical and Rehabilitation Robotics, Write a Robotics Buyer Brief or Robotics RFQ.